Whitepaper: Improving AAV vector quality with in-process monitoring of capsid formation
Large-scale production of high-quality adeno-associated virus (AAV) vectors for gene therapy is complex, often hindered by the challenge of ensuring appropriate DNA packaging. This can result in a significant proportion of empty or incorrectly filled capsids, rather than the desired full capsids that provide the therapeutic effect.
In our latest white paper “Improving AAV Vector Quality with In-Process Monitoring of Capsid Formation”, Nathan Sweeney, our ATMP Technical Strategy Director, and Hena Divanovic, our Process Development Scientist, explore how we’ve addressed these challenges through a breakthrough solution.
In partnership with Refeyn and Cell and Gene Therapy Catapult, and with the support from Innovate UK, we have developed a rapid, small-scale purification method that uses mass photometry to precisely monitor full, partial, and empty capsids throughout the AAV production process.
Our white paper provides insights into our innovative purification process established to optimize AAV manufacturing, highlighting the benefits of this solution.
Download the white paper here: https://lnkd.in/dD89F74Q